The management of neonatal pulmonary hypertension

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 97, Issue 3, 2012, Pages

  Dhillon, Rami ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM SULFATE; NITRIC OXIDE; PROSTACYCLIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; SILDENAFIL;

CYANOTIC HEART DISEASE; EXTRACORPOREAL OXYGENATION; HUMAN; LUNG DYSPLASIA; NONHUMAN; PREMATURITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; UNSPECIFIED SIDE EFFECT; VASODILATATION;

ANTIHYPERTENSIVE AGENTS; BRONCHOPULMONARY DYSPLASIA; EXTRACORPOREAL MEMBRANE OXYGENATION; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; PERSISTENT FETAL CIRCULATION SYNDROME;

EID: 84860839594     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2009.180091     Document Type: Review

References (44)

1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-54.
2. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
3. Kovacs G, Berghold A, Scheidl S, et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009;34:888-94.
4. Rudolph AM. High pulmonary vascular resistance after birth: I. Pathophysiologic considerations and etiologic classification. Clin Pediatr (Phila) 1980;19:585-90. (Pubitemid 11232082)
5. Rudolph AM. Fetal and neonatal pulmonary circulation. Am Rev Respir Dis 1977;115:11-18. (Pubitemid 8127961)
6. Gordon JB, Rehorst-Paea LA, Hoffman GM, et al. Pulmonary vascular responses during acute and sustained respiratory alkalosis or acidosis in intact newborn piglets. Pediatr Res 1999;46:735-41.
7. Marshall BE, Marshall C, Benumof J, et al. Hypoxic pulmonary vasoconstriction in dogs: effects of lung segment size and oxygen tension. J Appl Physiol 1981;51:1543-51. (Pubitemid 12209938)
8. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958;18:533-47.
9. Murphy JD, Rabinovitch M, Goldstein JD, et al. The structural basis of persistent pulmonary hypertension of the newborn infant. J Pediatr 1981;98:962-7. (Pubitemid 11093063)
10. Bush A, Busst CM, Knight WB, et al. Changes in pulmonary circulation in severe bronchopulmonary dysplasia. Arch Dis Child 1990;65:739-45. (Pubitemid 20220432)
11. Baquero H, Soliz A, Neira F, et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 2006;117:1077-83. (Pubitemid 46071498)
12. Cua CL, Blankenship A, North AL, et al. Increased incidence of idiopathic persistent pulmonary hypertension in Down syndrome neonates. Pediatr Cardiol 2007;28:250-4. (Pubitemid 46976641)
13. Singh BS, Clark RH, Powers RJ, et al. Meconium aspiration syndrome remains a significant problem in the NICU: outcomes and treatment patterns in term neonates admitted for intensive care during a ten-year period. J Perinatol 2009;29:497-503.
14. Levin DL, Mills LJ, Parkey M, et al. Constriction of the fetal ductus arteriosus after administration of indomethacin to the pregnant ewe. J Pediatr 1979;94:647-50. (Pubitemid 9125376)
15. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87. (Pubitemid 43209105)
16. Levin DL . Morphologic analysis of the pulmonary vascular bed in congenital left-sided diaphragmatic hernia. J Pediatr 1978;92:805-9. (Pubitemid 8314617)
17. Tracy ET, Mears SE, Smith PB, et al. Protocolized approach to the management of congenital diaphragmatic hernia: benefits of reducing variability in care. J Pediatr Surg 2010;45:1343-8.
18. Henderson-Smart DJ, De Paoli AG, Clark RH, et al. High frequency oscillatory ventilation versus conventional ventilation for infants with severe pulmonary dysfunction born at or near term. Cochrane Database Syst Rev 2009;3:CD002974.
19. Cools F, Henderson-Smart DJ, Offringa M, et al. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev 2009;3:CD000104.
20. Moore C, Tymvios C, Emerson M. Functional regulation of vascular and platelet activity during thrombosis by nitric oxide and endothelial nitric oxide synthase. Thromb Haemost 2010;104:342-9.
21. Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics 1998;101:325-34. (Pubitemid 28136402)
22. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev 2006;4:CD000399.
23. Parker TA, Ivy DD, Kinsella JP, et al. Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia. Am J Respir Crit Care Med 1997;155:743-6. (Pubitemid 27085829)
24. Golzand E, Bar-Oz B, Arad I. Intravenous prostacyclin in the treatment of persistent pulmonary hypertension of the newborn refractory to inhaled nitric oxide. Isr Med Assoc J 2005;7:408-9. (Pubitemid 40862051)
25. Kadowitz PJ, Joiner PD, Hyman AL, et al. Influence of prostaglandins E1 and F2alpha on pulmonary vascular resistance, isolated lobar vessels and cyclic nucleotide levels. J Pharmacol Exp Ther 1975;192:677-87.
26. Shekerdemian LS, Ravn HB, Penny DJ. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr Res 2004;55:413-18. (Pubitemid 38240818)
27. de Visser YP, Walther FJ, Laghmani el H, et al. Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respir Res 2009;10:30.
28. Huddleston AJ, Knoderer CA, Morris JL, et al. Sildenafil for the treatment of pulmonary hypertension in pediatric patients. Pediatr Cardiol 2009;30:871-82.
29. Joint Formulary Committee. British National Formulary. 2010-2011 edition. London: British Medical Association and Royal Pharmaceutical Society of Great Britain 2010.
30. McNamara PJ, Laique F, Muang-In S, et al. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care 2006;21:217-22. (Pubitemid 43850191)
31. Singh R, Choudhury M, Saxena A, et al. Inhaled nitroglycerin versus inhaled milrinone in children with congenital heart disease suffering from pulmonary artery hypertension. J Cardiothorac Vasc Anesth 2010;24:797-801.
32. Mugford M, Elbourne D, Field D. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst Rev 2008;3:CD001340.
33. Ho JJ, Rasa G. Magnesium sulfate for persistent pulmonary hypertension of the newborn. Cochrane Database Syst Rev 2007;3:CD005588.
34. Boo NY, Rohana J, Yong SC, et al. Inhaled nitric oxide and intravenous magnesium sulphate for the treatment of persistent pulmonary hypertension of the newborn. Singapore Med J 2010;51:144-50.
35. Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005;116:1353-60. (Pubitemid 46056482)
36. Balinotti JE, Tiller CJ, Llapur CJ, et al. Growth of the lung parenchyma early in life. Am J Respir Crit Care Med 2009;179:134-7.
37. Darlow BA, Graham PJ. Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev 2007;4:CD000501.
38. Viscardi RM, Hasday JD. Role of Ureaplasma species in neonatal chronic lung disease: epidemiologic and experimental evidence. Pediatr Res 2009;65:84R-90R.
39. Ballard HO, Shook LA, Bernard P, et al. Use of azithromycin for the prevention of bronchopulmonary dysplasia in preterm infants: a randomized, double-blind, placebo controlled trial. Pediatr Pulmonol 2010 Oct 20. [Epub ahead of print].
40. Halliday HL, Ehrenkranz RA, Doyle LW. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2010;1:CD001146.
41. Mourani PM, Sontag MK, Ivy DD, et al. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009;154:379-84, 384.e1-2.
42. Drossner DM, Kim DW, Maher KO, et al. Pulmonary vein stenosis: prematurity and associated conditions. Pediatrics 2008;122:e656-61.
43. Seale AN, Webber SA, Uemura H, et al. Pulmonary vein stenosis: the UK, Ireland and Sweden collaborative study. Heart 2009;95:1944-9.
44. Chakrabarti S, Tsao S, Vettukattil JJ, et al. Pulmonary vein stenosis mimicking chronic lung disease. Acta Paediatr 2003;92:857-8. (Pubitemid 37088660)